Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 3/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15900390 | 0.75 | MMP12 (0.47) | MMP12ALDH1A1HPGDXDHPDPK1 | |
| SCHEMBL14361905 | 0.74 | KDM4E (0.44) | MMP12ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL8044760 | 0.74 | ALDH1A1 (0.39) | ALOX5APFEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL8367003 | 0.74 | KDM4E (0.39) | ALOX5APFEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL29623085 | 0.74 | KDM4E (0.39) | ALOX5APFEN1ALDH1A1KDM4EMAPT | |
| SCHEMBL22440207 | 0.72 | MAPT (0.53) | ALDH1A1HPGDQPCTKDM4EMAPT | |
| SCHEMBL3229989 | 0.71 | KDM4E (0.50) | ALDH1A1HPGDKDM4EMAPTLMNA | |
| SCHEMBL22440179 | 0.70 | QPCT (0.53) | ALDH1A1QPCTKDM4ECDC7DBF4 | |
| SCHEMBL324999 | 0.69 | ALDH1A1 (0.39) | ALOX5APFEN1ALDH1A1QPCTKDM4E | |
| SCHEMBL21906548 | 0.69 | ALDH1A1 (0.39) | ALOX5APFEN1ALDH1A1QPCTBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970254-B1 | IMIDAZO PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9394317-B2 | Imidazo pyridine compounds | ELI LILLY AND COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2970254-A1 | IMIDAZO PYRIDINE COMPOUNDS | Eli Lilly and Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150368273-A1 | IMIDAZO PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2015-12-24 | — | — | US | disclosed |
| EP-2808020-A1 | Beta-Amyloid Pet Imaging Agents | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2014-12-03 | — | — | EP | disclosed |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2014143583-A1 | IMIDAZO PYRIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2021340-B1 | BETA-AMYLOID PET IMAGING AGENTS | US GOVERNMENT (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8703096-B2 | Beta-amyloid PET imaging agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2021340-A2 | BETA-AMYLOID PET IMAGING AGENTS | The Government Of The United States, As Represented by The Secretary Of Health And Human Services (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007124345-A2 | BETA-AMYLOID PET IMAGING AGENTS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368273-A1 | IMIDAZO PYRIDINE COMPOUNDS | ENPP2, TPX2, UACA | MMP12 1818/4885ALOX5AP 3758/4885FEN1 4461/4885 |
| US-20110008255-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | MMP12 2225/4885ALOX5AP 4330/4885FEN1 4183/4885 |
| US-20140341812-A1 | BETA-AMYLOID PET IMAGING AGENTS | APP, BACE1, PSEN1 | MMP12 2225/4885ALOX5AP 4330/4885FEN1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.